Vol. 10 nº 4 - Oct/Nov/Dec de 2016
Views & Reviews Pages 287 to 295

Cell-based technologies for Huntington's disease
Tecnologias celulares no doença de Huntington

Authors: Mônica Santoro Haddad1; Cristiane Valverde Wenceslau2; Celine Pompeia3; Irina Kerkis4


Descriptors: Huntington's disease, stem cells, safety issues, cell therapy.
doença de Huntington, células tronco, aspectos de segurança de células tronco, terapia celular.

Huntington's disease (HD) is a fatal genetic disorder, which causes the progressive breakdown of neurons in the human brain. HD deteriorates human physical and mental abilities over time and has no cure. Stem cell-based technologies are promising novel treatments, and in HD, they aim to replace lost neurons and/or to prevent neural cell death. Herein we discuss the use of human fetal tissue (hFT), neural stem cells (NSCs) of hFT origin or embryonic stem cells (ESCs) and induced pluripotent stem cells (IPSCs), in clinical and pre-clinical studies. The in vivo use of mesenchymal stem cells (MSCs), which are derived from non-neural tissues, will also be discussed. All these studies prove the potential of stem cells for transplantation therapy in HD, demonstrating cell grafting and the ability to differentiate into mature neurons, resulting in behavioral improvements. We claim that there are still many problems to overcome before these technologies become available for HD patient treatment, such as: a) safety regarding the use of NSCs and pluripotent stem cells, which are potentially teratogenic; b) safety regarding the transplantation procedure itself, which represents a risk and needs to be better studied; and finally c) technical and ethical issues regarding cells of fetal and embryonic origin.

A doença de Huntington (DH) é uma desordem genética que provoca a destruição progressiva dos neurônios no cérebro humano. A DH deteriora progressivamente as habilidades físicas e mentais humanas, e é incurável. Tecnologias terapêuticas baseadas em células representam novas alternativas para diversas doenças neurodegenerativas, pois visam substituir neurônios e/ou prevenir a morte neuronal. Nesta revisão discutirmos o uso de tecido fetal humano, células tronco neurais (CTN) de origem fetal ou de células tronco embrionárias ou células tronco pluripotentes induzidas, em estudos pré-clínicos e clínicos. Além disso, o uso terapêutico de células derivadas de tecidos não-neurais, como células tronco mesenquimais, também será discutido. Todos estes estudos provam o potencial do transplante celular na DH, demonstrando a sua habilidade em enxertar no encéfalo e diferenciar em neurônios in vivo, resultando em melhorias comportamentais e motoras em modelos animais da DH. Nós também discutimos que há muitos problemas a serem resolvidos quanto à terapia celular na DH, tais como: a) questões associadas à segurança do uso de CTNs, as quais são consideradas potencialmente teratogênicas; b) segurança do procedimento de transplante intracerebral, que representa um risco ao paciente; c) e, finalmente, questões técnicas e éticas associadas ao uso de células de origem fetal e embrionária.


American physician George Huntington first described the disease in 1872. Huntington's disease, which is also denominated Huntington's syndrome or Huntington's chorea, is a chronic, progressive and fatal neuropsychiatric disorder. HD is a hereditary autosomal dominant disease - 50% of children born from disease carriers inherit HD. This disease induces destruction of neurons in the subcortical parts of the brain hemispheres (mainly - striped body): mostly the caudate and lenticular nuclei. HD leads to the expansion of the anterior horns of the lateral ventricles - a sign used to identify HD during neuroimaging.1,2

Neuronal death in HD occurs as a result of abnormal synthesis of the Huntingtin protein (HTT), which is particularly prone to misfold and accumulates, leading to axonal and synaptic dysfunction. This accumulation of the misfolded mutant Huntingtin protein (mHTT) may affect intracellular transport of the protein or impair protein degradation by the proteasome, leading to autophagy.3,4 However, it is not clear how mHTT accumulates in the neuronal processes and induces an early pathological event in the brains of HD carriers.

There are two types of disease: adult-onset HD or juvenile HD, defined by the manifestations of the first signs of the disease. In adult-onset HD, the first symptoms usually appear after age 30, but possibly may start earlier.3 HD is characterized by a combination of motor and neuropsychiatric disorders that can occur simultaneously or in succession. Movement disorders include involuntary grimace, excessive gestures and others. Neuropsychiatric disorders, which usually appear after the motor disorders, may affect both cognitive and intellectual functions, as well as emotional status. Cognitive dysfunction is most often expressed in problems of visual-spatial orientation.4,5 Memory can also suffer, especially in the ability to retain the information necessary for workflow. Patients may not be able to plan and organize their activities. With time, symptom severity increases, reaching that of dementia. Emotional and behavioral disorders primarily present themselves by the emergence of unmotivated aggression and irritability (observed in more than half of patients).6,4 Approximately one third of patients suffer from depression. Remarkably, the cause of death among HD carriers is not the disease itself, but accompanying illnesses, such as pneumonia and heart failure; approximately 30% of patients die from suicide. Juvenile HD is a less common, early-onset form of HD that starts in childhood or adolescence. Juvenile HD evolves very rapidly and presents severe symptoms that quickly lead to disability.7

Currently, the diagnosis of HD is based on clinical (see above), genotypic and imaging findings. Since the discovery of the HD gene in 1993, a genetic test was developed that analyzes the HD mutation by counting the number of CAG repeats in the HD gene. This analysis enables direct confirmation of the diagnosis of HD in patients that exhibit HD-like symptoms. Using a blood sample, it is possible to demonstrate that an individual who does not have HD usually has 28 or fewer CAG repeats. HD carriers have 40 or more repeats, while a small proportion of individuals show a number of repeats that fall within a borderline region (Table 1).8

Magnetic Resonance Imaging (MRI) is a neuroimaging modality that provides the greatest spatial and contrast resolution for assessing the type of lesion associated with HD and allows the most precise diagnosis. Magnetic resonance spectroscopy (MRS) can also be used to show impaired brain energy metabolism associated with, for example, increased regional brain lactate that plays an important role in the pathogenesis of HD. In addition, computerized tomography (CT) scan, which determines the damaged areas of the brain, is also useful in HD diagnosis.9-14

In conclusion, neuroimaging, particularly MRI, remains a keystone in diagnosing and assessing the severity of HD. Genetic testing is extremely important to confirm the diagnosis, especially if the family history is not forthcoming and, moreover, genetic counseling of HD patients may provide guidance on the implications of the disease.

No cure is currently available. All HD treatment focuses on symptom relief, thus achieving only temporary improvement of the patient's neurological status. Although such treatment improves patient quality of life, the progress of the disease is unchanged and the neuronal loss persists.

Neuronal cells and different types of stem cells are a promising raw material for the development of new therapeutic strategies in HD: they may prevent neuronal loss and consequently delay the disease progress.


The main goal of cell-based technologies is to repair the mechanisms underlying disease initiation and progression, achieved by replacement of dead or defective cells and through the trophic effect, which some cell types may confer after their transplantation into the injured site.15-17 Different cell types can be utilized in these therapies, including fetal cells and tissues, progenitor cells or primary stem cells isolated from different tissues of an adult organism.15,18-21 This review covers the current state of cell-based therapies designed for HD. Some of these therapies are still at an initial stage of development and must be tested in animal models (preclinical studies) before they can be approved by regulatory agencies for use in clinical trials (involving humans). On the other hand, only a few studies have already reached clinical trials as will be discussed later.


Human fetal tissue (hFT) has been used in basic research for decades.18 Clinical studies involving hFT aim to rebuild brain structures and neural circuitries by transplantation of hFT into the damaged central nervous system (CNS) in HD patients. The hFT is derived from elective surgical terminations of pregnancy in fetuses at between 6 and 12 weeks of gestation. In the case of the hFT used for clinical transplantation, the tissue consists of the whole ganglionic eminence, corresponding to the striatal primordium that ultimately develops into the caudate and putamen.22-26 HD patients may receive unilateral or bilateral hFT cell transplantation from several donated embryos (between five and nine).

Generally, the surgery and procedure of hFT transplantation into the brain of HD patients is considered to be safe.22,26 However, one study reported that three out of seven HD patients that underwent bilateral stereotactic transplantation developed subdural haemorrhages and two others required surgical drainage.24 No patients had adverse effects to the associated cyclosporin immunosuppression, nor did any patients exhibit deterioration following the procedure.26 The immunosuppressive protocol adopted in these studies efficiently prevents immune rejection of the graft. Histological evidence of immune rejection, including the appearance of microglia and macrophages in the hFT transplantation sites, has never been observed.25,26

All these studies show the ability of hFT cells to delay disease progression and provide stabilization or improvement in several neurological indices of cognitive functioning, although these changes were not uniform across HD patients.22,24-26

MRI analyses showed hFT graft survival and even growth without damage to the surrounding tissue.

Another key concern that needs to be considered is the safety of hFT transplantation regarding tumor formation.27 Although the majority of the studies do not show tumor formation after hFT transplantation,26 recently, one study emphasized the instability and risk of hFT grafts: the patient enrolled in a NIH-funded study did not show any behavioral improvement after hFT transplantation into the brain, yet presented a growth of tissue mass, termed "graft overgrowth".28 Such graft overgrowth may be explained by the presence of immature neuroepithelial cells actively dividing cells that express NSC markers such as Sox2, which are occasionally preserved in the hFT-derived cell suspension used for transplantation.28 Both these studies26,28 compromised the safety of hFT transplantation and indicate the need for further in-depth studies using chemical and transgenic preclinical models and a large number of animals. Additionally, it has been shown that not only hFT transplantation, but also fetal stem cell transplantation, may sporadically lead to brain tumor formation at the site of transplantation.29 Although these cells are subject to restrictions regarding safety, they are able to recover medium spiny neurons (MSN).

A postmortem analysis of a brain carried out six months after a patient underwent transplantation demonstrated that hFT-derived cells were able to differentiate into MSNs which expressed dopamine-receptor related phosphoprotein (32 kDa) (DARPP-32), the neuronal nuclear antigen (NeuN), calretinin that can protect the MSNs against neurodegeneration in HD, and somatostatin, which is increased in the basal ganglia in HD.20,28 These results are important given that HD is considered a disease of the striatum, characterized by vulnerability to degeneration and death of MSNs.1,2 Also, hFT graft-derived astrocytes have also been observed after transplantation.20 Astrocytes are a sub-type of glial cells in the CNS that are protective neurons against excitotoxicity by removing excessive glutamate from the extracellular space. Astrocyte recovery after hFT transplantation is a highly beneficial effect of the procedure, since in the HD brain, where mHTT accumulates in glial nuclei, there is a decrease in the expression of glutamate transporters in neurons and astroglial cells.30

Misfolded mHTT protein aggregates, which accumulate as cytoplasmic aggregates and nuclear inclusions, are a hallmark feature of HD.3,4 As we mentioned above, mHTT aggregates clump together and damage neurons. Recent research suggests that these mHTT proteins may also be transmitted from neuron to neuron. Interestingly, this hypothesis of pathogenic protein spread during neurodegeneration has been critically evaluated recently by Walsh,31 who suggests experimental approaches to rigorously test its fundaments. However, the formation of mHTT aggregates does not seem to be a prerequisite for HD, as shown by a clinical study carried out with transplanted hFT in HD patients, whereby a postmortem histological analysis performed 18 months after the treatment did not show the presence of neuronal protein aggregates of mHTT within the hFT graft.32 In this context, all experimental data that support or detract from this hypothesis are of great importance.


To date, of the possible transplant options that can benefit HD patients, only hFT has been used in clinical HD studies. Thus, for the purposes of the present review, we have provided a short explanation about animal HD models, which are most commonly used in preclinical studies for other treatment approaches. Preferably, the HD animal model should provide similar genotypes and phenotypes as human HD.15,33 Chemical HD animal models are commonly induced by treatment with quinolinic acid (QA)19,34,35 or 3 nitropropionic acid (3-NP)36-39 Both of these chemical agents induce rapid development of progressive HD, early disease onset, abnormal behavior, and neuropathological features. These models are useful for rapid evaluation of the therapeutic hypothesis (acute models).15 In contrast, transgenic models are providing more precise systems for disease replication that allow evaluation of the therapy of interest in slow progressive degeneration.40

Transgenic models result from the random insertion of a portion of the human HTT gene containing the coding region for the polyglutamine repeat into the mouse genome, under control of several promoters. The most commonly used mouse HD models are R6/1, R6/2 and N171-Q82, which express truncated N-terminal fragments.41 Moreover, in contrast to the chemical models, the transgenic HD models are powerful research tools because they recapitulate specific HD features such as the accumulation of intracellular aggregates of mHTT in the cytoplasm or nucleus of neurons, known as inclusion bodies (IBs) (Figure 1).

Figure 1. Aggregate formation by HTT mutation in neuron cell derives inclusion bodies: [A] Inclusion body accumulation at axons and dendrites (cytoplasm); and [B] nucleus. Black arrows indicate inclusion bodies.

Rodent HD models such as rats and mice are widely used to investigate cell-based therapy technologies.40 More recently, a transgenic nonhuman primate model in rhesus monkeys (Macaca mulatta) of HD was developed.42 Also, transgenic HD models were established in large farm animals such as sheep (Ovis aries)43 and Tibetan miniature pigs.44 However, transgenic HD models in large animals are high cost and technically difficult to use in routine cell-based therapy testing.


It was long thought that neural cells could not undergo regeneration in injured or diseased human brain. However, advanced studies with NSCs in injured animal models have shown the regenerative potential of these cells.15,45,46 NSCs are self-renewing cells able to generate neurons, glial cells and astrocytes. NSCs can be derived from embryonic, fetal or adult tissues.47,48 Embryonic-fetal neural precursor cells (NPCs) are composed of a mixed population of multipotent NSCs and transit amplifying/intermediate progenitor cells (NPGCs) (Figure 2).49

Figure 2. Hierarchical relationship between types of brain-derived stem cells.

Discrete populations of NSCs can be found in specific areas of the postnatal human brain and seem to play an important role in postnatal growth as well as in recovery of neural tissue from injury, anoxia, or disease.50 NSCs can be isolated at different stages of development and cultivated in vitro under appropriate culture conditions as neurospheres, which are free-floating clusters of round multicellular spheroids, or, alternatively, as adherent NSCs (Figure 2). Neurospheres, when allowed to adhere to the substrate, start to produce neural rosettes (Figure 2), which are long-term self-renewing neuroblast-like cells. Murine or human NSCs have been used in preclinical studies to show the potential therapeutic effect of NSC-based technologies on neurogenesis in HD animal models.34,51,52 These studies showed that transplantation of NSCs improves motor function, extends life span and even lessens mHTT intracellular aggregate formation. In these studies, the cells were injected mainly by the intrastriatal route due to the inability of NSCs to pass though the blood brain barrier (BBB). NSCs exhibit robust engraftment at the site of injury. However, the differentiation of these cells into neural cells is still controversial.34,37,38,51-53

The evaluation of teratogenicity of embryo-fetal derived NSCs is still lacking, although it is essential for the further translation of these studies into clinical trials. Due to the commitment of NSCs to neural fate, they may be considered an ideal cell type for the treatment of neurological diseases. However, NSCs are difficult to obtain in therapeutically significant quantities and pose serious ethical and religious limitations given that they are obtained from aborted fetuses.15


There is no doubt that hFT and NSCs are important in many research areas, especially in studies of human neurodegenerative diseases. HFT and NSCs help scientists investigate many aspects of basic science that cannot be studied in any other way. However, isolation of hFT and NSCs from hFT raises major ethical, political and religious controversies.21,54 We believe that these ethical issues, associated with the limited number of experiments carried out so far, only minor success in these experimental therapies, as well as the potential teratogenicity of fetal and embryonic cells, are reasons why the use of ethically-accepted alternatives is starting to dominate the field, especially in Brazil.


Embryonic stem cells (ESCs) are pluripotent cells isolated from the inner cell mass of early embryos. These cells can generate a whole organism when re- introduced back into the embryonic environment (e.g. blastocysts) (Figure 3). ESCs are also able to form gametes - reproductive cells. Additionally, ESCs form noncancerous tumors called teratomas, which is one of their fundamental traits.55,56

Figure 3. Stem cell types used so far in clinical and preclinical studies of HD. [A] hFT is isolated from fetuses at between 6 and 12 weeks of gestation and composed of NPCs (NSC+NPGC) and many other fetal cell types that are used in clinical studies (G). Similarly, hFT, after further purification, can be used as a source of NSCs, which, in turn, are also used in clinical studies (G). [B] ESCs can be isolated from early human embryos (B), and form rosette colonies (E) and neurospheres (F). Both rosette- or neurosphere-forming NSCs (A, B) have been used in preclinical studies (H). [C] MSCs are isolated from bone marrow, adipose tissue or umbilical cord and have a different morphology in vitro than that of NPCs or ESCs, being fibroblast-like (C). [D] iPSCs can be obtained from many adult tissues (C) via reprogramming; these cells are morphologically similar to ESCs (B). However, unlike ESCs, iPSCs are obtained from adult cells and therefore are not subject to the same major ethical considerations as those for ESC isolation, which require human embryos; iPSCs also produce NSCs rosette-forming colonies (E) or neurospheres (F), which have been used in preclinical studies (H).

As mentioned before, tumor formation is a major safety concern for those who hope to use the cells therapeutically.57 Due to this feature of ESCs, they cannot be used unspecialized in preclinical and clinical studies. To analyze the therapeutic potential of human ESCs in HD animal models, they have been reversed to NPCs that have been transplanted directly into the striatum of the animal models. Different types of NPCs may be obtained, which depends on the protocol of human ESC differentiation.58-60 Rosette-forming ESC-derived NPCs (Figure 3) are unable to differentiate in vivo into medial spiny neurons (MSN), which is a principal target of HD therapies.59

However, they have the capacity to differentiate into other neuron types and into astrocytes. Preclinical short-term studies show effective recovery of motor deficit after hESC-derived NSC transplantation in the QA rat model.58-60 The main problem in using ESC-derived NPCs in the clinic is the need to control their proliferation in order to avoid neural cell graft overgrowth.59,60

Laboratory-grown induced pluripotent stem cells (iPSCs) are a type of pluripotent cell that can be generated directly from adult cells (Figure 3). Currently, practically any type of somatic adult cell can be reprogrammed back into an embryonic-like pluripotent state. The iPSCs share all principal characteristics of ESCs, having the ability of long-term self-renewal, maintaining an unspecialized state; and giving rise to (under specific treatments) specialized cell types and teratomas when injected in vivo.61,62 However, the pluripotential ability of the iPSCs may be influenced by the adult donor cell source.63,64 The therapeutic potential of hiPSCs, as well as that of hiPSC-derived NPCs, has also been investigated using HD animal models.65-67 These cells have been transplanted into both chemical65 and transgenic HD rodent models via the ipsilateral ventricular route.67 These cells graft into recipient brains and differentiate into GABAergic MSNs65,67,68 and astrocytes.68 After transplantation, a modest reduction in striatal neuronal atrophy, a hallmark of HD disease that appears before the onset of motor symptoms, can be observed.68,69

After transplantation of NSCs derived from iPSCs, short- and medium-term functional motor improvements have been documented in comparison with sham group animals.65,67,68 However, long-term motor functional recovery from HD followingESC- and iPSC-derived NSC transplantation still needs to be further evaluated.


MSCs can be found in virtually all postnatal tissues, including the embryonic annexes (umbilical cord and placenta), bone marrow and adipose tissue. Isolation of these cells is associated with fewer ethical concerns when compared with ESCs. MSCs have a fibroblast-like morphology (Figure 3), express a set of specific markers and adhere to plastic. They are of exceptional interest because they are unspecialized cells capable of self-renewal and differentiation into specific cell types, especially into mesoderm derivatives.70-73 However, a growing number of studies has demonstrated their capacity to also differentiate into neural cells.74 Furthermore, the number of clinical trials using MSCs is rising every year and, at least, the clinical safety of these cells has been confirmed.75

The biological function of MSCs is to replace tissues in response to normal cellular turnover or trauma.76 It has been also suggested that these cells can be recruited to nascent microvascular walls during development and postnatal growth.77 Accordingly, MSCs in their anatomical sites - stem cell niches - have their growth arrested until they are triggered to restart proliferation and even differentiation in response to physiological cues, such as tissue turnover or repair, or experimentally, when isolated and cultivated in vitro. In bone marrow, for example, subendothelial osteoprogenitors become stem cells acting as pericytes in different postnatal tissues. Therefore, as an alternative to differentiation, tissue-specific MSCs may function to support the regeneration of other local cell types. Such support is carried out by MSCs after transplantation into the unhealthy organism via the secretion of a variety of bioactive molecules such as cytokines, which have 'trophic activities' that can promote a regenerative microenvironment.16,17 MSCs also benefit tissue reconstruction by stimulating angiogenesis, the production of immunomodulatory mediators and even by delivering other molecules to the injured site. MSCs also act by reducing chronic inflammation, inhibiting apoptosis and decreasing scar formation. They are able to stimulate mitosis of tissue-intrinsic stem cells and reduce the destructive effects of oxidative stress.16,17,78 MSCs express very low levels of MHC class I proteins and lack MHC class II proteins, and can therefore be transplanted into other organisms of the same or different species without rejection.73,79

MSCs isolated from bone, adipose tissue and umbilical cord have been used in different chemical (QA and 3-NP) and genetic animal models (R6/2-J2, N171-82Q, R6/2) of HD, which were transplanted using the intracerebral route (directly into the striatum). These studies demonstrate that MSC transplantation leads to behavioral and memory improvements, reduced brain damage, improvement of striatal degeneration, and enhanced expression of several striatal growth factors, which are attributed to the neuroprotective effect of MSCs. MSC transplantation shows robust cell engraftment at the site of lesion, as well as the ability of these cells to migrate to adjacent areas.80-83 Although the actual differentiation of MSCs into neurons is controversial, it is not required to justify the beneficial activity of these cells in HD. Furthermore, MSC transplantation has never been shown to lead to teratoma or graft overgrowth formation, indicating the safety of these cells, at least in animal models.


Neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), are essential contributors of CNS neuron function. Studies demonstrate their reduced availability in diseased brains, thus suggesting that they play an important role in neurological disorders and, in particular, in HD.84,85 Under non-pathologic conditions, BDNF is synthesized in the cortex, the substantia nigra pars compacta, the amygdala, and in the thalamus. All these regions supply the striatum with BDNF.86,87 In HD, the deficit of BDNF in the striatum may be due to reduced BDNF gene transcription in the cerebral cortex or reduced BDNF vesicle transport (or both).88,89 The decrease in BDNF expression observed in HD impairs dopaminergic neuronal function, which may be associated with HD motor disturbances. As a result, many studies have been carried out to examine whether increasing BDNF levels may help treat HD.37,83,88

NPCs and MSCs, besides their differentiation ability to produce neurons, have been extensively investigated with respect to neurotrophic factor secretion.37,90 Studies have shown that MSCs derived from adipose tissue and bone marrow are able to secrete BDNF in vitro.83,91-93 However, MSCs secrete BDNF at low levels, which are dependent on tissue source used for MSC isolation and on donor characteristics.92,94,95

Therefore, recent studies have generated NSCs derived from ESCs that overexpress BDNF in order to evaluate whether they have enhanced therapeutic abilities in HD. Neurons derived from BDNF-GFP-expressing ESCs harbor a more complex dendritic morphology and differentiate into the GABAergic lineage.96


Great advances have been made in cell-based therapies over recent decades and it is expected that, in the future, such therapies will be provided alone or in combination with traditional medication, new small molecule drugs and biological drugs to patients who suffer from neurological conditions such as HD. Figure 2 summarizes the major advances that have been made in cell-based technologies and their use for the treatment of HD in clinical and preclinical studies.

Notably, all these cell-based technologies may be roughly divided into two: NSC- and MSC-based, since none of the pluripotent cells (such as ESCs or IPSCs) can be used intact/unspecialized due to the risk of teratogenicity after transplantation into the lesion site. NSCs derived from iPSCs look set to substitute hFT, fetal- as well as ESC-derived NSCs, thus avoiding ethical and religious considerations.

Another important conclusion is that these different cell types produce very similar clinical outcomes and therefore can be used interchangeably. The major advantage of MSCs over NSC derived from different cell types is that they do not produce teratomas or graft overgrowth. Additionally, they express neurotrophic factors, albeit at low levels, which are apparently important for HD improvement.

The major problem of cell-based technologies in HD concerns the route of administration, which is usually intracerebral. This will be a great obstacle for the use of cell-based technologies in HD patients, which is a genetic disease and may require more than one cell transplantation. None of the clinical and preclinical HD studies have yet used the systemic intravenous route,21,24,26,27 probably due to the fear that these cells will not penetrate the BBR in significant numbers. However, we believe that MSCs can be systemically administrated and have tropism for sites of injury, even the brain, as in the case of HD. However, further studies are necessary to better understand this administration route and prove its efficacy and safety in HD.

Author contribution. MSH: drafting the article, critical revision of the article, final approval of the version to be published; CVW: data collection, drafting the article, critical revision of the article, final approval of the version to be published; CP: critical revision of the article and final approval of the version to be published. IK: design of the study, drafting the article, critical revision of the article, final approval of the version to be published.


1. Davies S, Ramsden DB. Huntington's disease. Mol Pathol. 2001;54(6): 409-13.

2. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-84.

3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.

4. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83-98.

5. Hayden MR. Huntington's chorea. London: Springer; 1981.

6. Folstein SE. The psychopathology of Huntington's disease. Res Publ Assoc Res Nerv Ment Dis. 1991;69:181-91.

7. Ribaï P, Nguyen K, Hahn-Barma V, Gourfinkel-An I, Vidailhet M, Legout A, et al. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch Neurol. 2007;64(6):813-9.

8. Agostinho LA, dos Santos SR, Alvarenga RMP, Paiva CLA. A systematic review of the intergenerational aspects and the diverse genetic profiles of Huntington's disease. Genet Mol Res. 2013;2(2):1974-81.

9. Ho VB, Chuang HS, Rovira MJ, Koo B. Juvenile Huntington disease: CT and MR features. AJNR Am J Neuroradiol. 1995;16(7):1405-12.

10. Paulsen JS, Zimbelman JL, Hinton SC, Langbehn DR, Leveroni CL, Benjamin ML, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. AJNR Am J Neuroradiol. 2004;25(10):1715-21.

11. Dormont D, Seidenwurm DJ. Expert Panel on Neurologic Imaging; American College of Radiology. Dementia and movement disorders. AJNR Am J Neuroradiol. 2008;29(1):204-6.

12. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci. 2012;11:199-251.

13. Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82(3):279-81.

14. Macerollo A, Perry R, Stamelou M, Batla A, Mazumder AA, Adams ME, et al. Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty. Eur J Neurol. 2014;21(2):e16-7.

15. Kerkis I, Haddad MS, Valverde CW, Glosman S. Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges.Stem Cell Res Ther. 2015;6:232.

16. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076-84.

17. Caplan AI. MSCs: the new medicine. In: Vertes AA, Qureshi N, Caplan AI, Babiss LE, editors. Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies. John Wiley & Sons; 2013.

18. Fetal Research and Applications: A Conference Summary. Conference Committee on Fetal Research and Applications, Institute of Medicine. National Academy Press, Washington, D.C. 1994.

19. Bantubungi K, Blum D, Cuvelier L, Wislet-Gendebien S, Rogister B, Brouillet E, et al. Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci. 2008;37:454-70.

20. Capetian P, Knoth R, Maciaczyk J, Pantazis G, Ditter M, Bokla L, et al. Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation. Neuroscience. 2009;160(3):661-75.

21. Freeman TB, Cicchetti F, Bachoud-Levi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol. 2011;227:1-9.

22. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol. 1998;149(1):97-108.

23. Philpott LM, Kopyov OV, Lee AJ, Jacques S, Duma CM, Caine S, et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant. 1997;6(3):203-12.

24. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology. 2002;58:687-95.

25. Gallina P, Paganini M, Lombardini L, Saccardi R, Marini M, De Cristofaro MT, et al. Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp Neurol. 2008;213(1):241-4.

26. Gallina P, Paganini M, Lombardini L, Giordano G, Mascalchi M, Romoli AM, et al. Progress in restorative neurosurgery: human fetal striatal transplantation in Huntington's disease. J Neurosurg Sci. 2011;55(4):371-81.

27. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108:1340-7.

28. Keene CD, Chang RC, Leverenz JB, Kopyov O, Perlman S, Hevner RF, et al. A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 2009;117(3):329-38.

29. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009; 6(2):e1000029.

30. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001;58(3):365-70.

31. Walsh DM, Selkoe DJ.A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci. 2016;17(4): 251-60.

32. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A. 2000;97(25):13877-82.

33. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. ILAR J. 2007;48(4):356-73.

34. Lee ST, Chu K, Park JE, Lee K, Kang L, Kim SU, et al. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci Res. 2005;52:243-9.

35. Pierozan P, Fernandes CG, Dutra MF, Pandolfo P, Ferreira F, de Lima BO, Porciúncula L, Wajner M, Pessoa-Pureur R.Biochemical, histopathological and behavioral alterations caused by intrastriatal administration of quinolic acid to young rats. FEBS J. 2014;281(8):2061-73.

36. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3- nitropropionic acid. J Neurochem. 1993;60(1):356-9.

37. Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB, et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis. 2004;16:68-77.

38. Rosenstock TR, Carvalho AC, Jurkiewicz A, Frussa-Filho R, Smaili SS. Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid. J Neurochem. 2004;88(5):1220-8.

39. Roberts TJ, Price J, Williams SC, Modo M. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience. 2006;139:1187-99.

40. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci. 2013;14(10):708-21.

41. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506

42. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature. 2008;453:921-4.

43. Jacobsen JC, Bawden CS, Rudiger SR, McLaughlan CJ, Reid SJ, Waldvogel HJ, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet. 2010;19(10):1873-82.

44. Yang D, Wang CE, Zhao B, Li W, Ouyang Z, Liu Z, et al. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet. 2010;19(20):3983-94.

45. Armstrong RJ, Watts C, Svendsen CN, Dunnett SB, Rosser AE. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant. 2000;9(1):55-64.

46. Doeppner TR, Kaltwasser B, Bähr M, Hermann DM. Effects of neural progenitor cells on post-stroke neurological impairment-a detailed and comprehensive analysis of behavioral tests. Front Cell Neurosci. 2014;8:338.

47. Doe CQ. Neural stem cells: balancing self-renewal with differentiation. Development. 2008;135:1575-87

48. Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science. 1999;285(5428):754-6.

49. Calof AL, Bonnin A, Crocker C, Kawauchi S, Murray RC, Shou J, et al. Progenitor cells of the olfactory receptor neuron lineage. Microsc Res Tech. 2002;58(3):176-88.

50. Gage FH, S Temple. Neural stem cells: Generating and regenerating the brain. Neuron. 2013;80:588-601.

51. McBride JL, Behrstock SP, Chen EY, Jakel RJ, Siegel I, Svendsen CN, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004;475:211-9.

52. Johann V, Schiefer J, Sass C, Mey J, Brook G, Kruttgen A, et al. Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington's disease. Exp Brain Res. 2007;177:458-70.

53. Vazey EM, Chen K, Hughes SM, Connor B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp Neurol. 2006;199: 384-96.

54. Lunn JS, Sakowski SA, Hur J, Feldman EL. Stem cell technology for neurodegenerative diseases. Ann Neurol. 2011;70(3):353-61.

55. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7.

56. Wu J, Yamauchi T, Izpisua Belmonte JC. An overview of mammalian pluripotency. Development. 2016;143(10):1644-8.

57. Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N. The anti-apoptotic gene surviving contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol. 2009;27(3):281-7.

58. Song J, Lee ST, Kang W, Park JE, Chu K, Lee SE, et al. Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. Neurosci Lett. 2007;423(1):58-61.

59. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA. 2008;105(43):16707-12.

60. Vazey EM, Dottori M, Jamshidi P, Tomas D, Pera MF, Horne M, et al. Comparison of transplant efficiency between spontaneously derived and noggin- primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease. Cell Transplant. 2010;19(8):1055-62.

61. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.

62. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72.

63. Beltrão-Braga PC, Pignatari GC, Maiorka PC, OliveiraNA, Lizier NF, Wenceslau CV, et al. Feeder-free derivation of inducedpluripotent stem cells from human immature dental pulp stem cells. Cell Transplant. 2011;20(11-12):1707-19.

64. Quattrocelli M, Giacomazzi G, Broeckx SY, Ceelen L, Bolca S, Spaas JH, et al. Equine-Induced Pluripotent Stem Cells Retain Lineage Commitment Toward Myogenic and Chondrogenic Fates. Stem Cell Reports. 2016;6(1):55-63.

65. Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, et al. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells. 2012;30(9):2054-62.

66. Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, et al. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol Brain. 2012;5:17.

67. Jeon I, Choi C, Lee N, Im W, Kim M, Oh SH, et al. In Vivo Roles of a Patient- Derived Induced Pluripotent Stem Cell Line (HD72-iPSC) in the YAC128 Model of Huntington's Disease. Int J Stem Cells. 2014;7(1): 43-47.

68. Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, et al. Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model. PLoS One 2014;9(7):e101185.

69. Montserrat N, Nivet E, Sancho-Martinez I, Hishida T, Kumar S, Miquel L, et al. Reprogramming of human fibroblasts to pluripotency with lineage specifiers. Cell Stem Cell. 2013;13(3):341-50.

70. Friedenstein AJ. Osteogenic stem cells in bone marrow. In: Heersche JNM, Kanis JA, editors. Bone and Mineral Research. Amsterdam: Elsevier; 1990:243-72.

71. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-50

72. Caplan AI. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng. 2005;11(7-8):1198-211.

73. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.

74. Bianco P, Robey PG, Simmons PJ. Mesenchymal Stem Cells: Revisiting History, Concepts and Assays. Cell Stem Cell. 2008;2(4):313-9.

75. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2(3):e91-100.

76. Kørbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003;349(6):570-82

77. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9: 685-93.

78. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402.

79. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252-60.

80. Snyder BR, Chiu AM, Prockop DJ, Chan AW. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One. 2010;5:e9347.

81. Lee ST, Chu K, Jung KH, Im WS, Park JE, Lim HC, et al. Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol. 2009;66:671-81.

82. Moraes L, Vasconcelos-dos-Santos A, Santana FC, Godoy MA, Rosado-de-Castro PH, Jasmin, et al. Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington's disease. Stem Cell Res. 2012;9:143-55.

83. Rossignol J, Boyer C, Leveque X, Fink KD, Thinard R, Blanchard F, et al. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res. 2011;217:369-78.

84. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493-8.

85. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5(6):311-22.

86. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389(6653):856-60.

87. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde corticalbrain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250-8.

88. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007;81(5-6):294-330.

89. Baydyuk M, Xu B. BDNF signaling and survival of striatal neurons. Front Cell Neurosci. 2014;8:254.

90. Lu P, Jones LL, Snyder EY, Tuszynski MH. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol. 2003;181(2):115-29.

91. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor- secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J. 2009;11(4):201-4.

92. Zemelkov VI, Kozhukharova IV, Kovaleva ZV, Domnina AP, Pugovkina NA, Fridlianskaia II, et al. BDNF secretion in human mesenchymal stem cells isolated from bone marrow, endometrium and adipose tissue. Tsitologiia. 2014;56(3):204-11.

93. Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M, et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther. 2005;11(1):96-104

94. Razavi S, Razavi MR, Zarkesh Esfahani H, Kazemi M, Mostafavi FS. Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells. Dev Growth Differ. 2013;55(6):648-55

95. Kim SJ, Moon GJ, Chang WH, Kim YH, Bang OY; STARTING-2 (STem cell Application Researches and Trials In NeuroloGy-2) collaborators. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trialal. Trials. 2013;14:317.

96. Leschik J, Eckenstaler R, Nieweg K, Lichtenecker P, Brigadski T, Gottmann K, et al. Embryonic stem cells stably expressing BDNF-GFP exhibit a BDNF-release- dependent enhancement of neuronal differentiation. J Cell Sci. 2013;126:5062-73.

1. MD. Faculdade de Medicina da Universidade de São Paulo - Neurologia São Paulo, São Paulo, SP, Brazil
2. MD. Instituto Butantan - Genética, São Paulo, SP, Brazil
3. MD. Instituto Butantan - Genética, São Paulo, SP, Brazil
4. MD, PhD. Instituto Butantan - Genética, São Paulo, São Paulo, Brazil

Irina Kerkis
Instituto Butantan - Genética
Avenida Vital Brasil, 1500
05503-900 São Paulo SP - Brazil
E-mail: ikerkis@butantan.gov.br

Received October 07, 2016.
Accepted in final form November 10, 2016.
Disclosure: The authors report no conflicts of interest.

This study was conducted at the Instituto Butantan - Genética, São Paulo, SP, Brazil.
dementia dementia dementia


Home Contact